236 results about "Weight loss" patented technology

Described herein is a composition comprising at least one of a lotus leaf extract (LLE), a chrysanthemum extract (CME), and a Pu'er tea extract (PTE), the composition having an agonistic effect on the glucagon-like peptide-1 receptor (GLP-1R). In addition, compositions comprising a mixture of LLE, CME, and PTE are described herein. Also described are methods of using the described compositions, e.g., for supporting weight loss efforts in a subject in need thereof.

The present invention provides compositions comprising one or more ACAT inhibitors and one or more GLP-1 receptor agonists (GLP-1 RAs). The combination therapy reduces side effects associated with high-dose GLP-1 RA monotherapy and provides durable management of weight loss by suppressing rebound of body weight, blood glucose, and cholesterol levels after treatment.

The invention relates to the technical field of rice product processing, in particular to high-toughness nutritional rice noodles as well as a preparation method and application thereof. The novel food raw material peach gum and other raw materials are scientifically proportioned, and a twin-screw extrusion technology is combined to generate the high-toughness rice noodles. By optimizing the raw material ratio and process parameters, the toughness, nutritional value and functionality of the rice noodles are remarkably improved; functional dietary fibers are introduced into the formula of the rice noodles, so that the starch digestion rate is regulated and controlled, and the intestinal function is improved. The high-toughness nutritional rice noodles developed by the invention show a relatively balanced characteristic in texture characteristic detection, have unique advantages and potentials in the aspects of controlling the starch digestion rate and improving the intestinal function, can effectively maintain the nutrition and taste of food materials, are compound rice noodles with the characteristics of high toughness, nutrient enrichment and chronic disease adaptation, and have a broad market prospect. The food is suitable for diabetics and weight-losing people to eat.

The invention belongs to the related technical field of pet prescription food products, and particularly relates to a prescription food for pet dogs with acute intestinal inflammation and a preparation method of the prescription food, the prescription food comprises various components such as rice, barley, chicken powder and corn protein powder, and probiotics are self-made and comprise bifidobacterium, lactobacillus acidophilus and lactobacillus casei. The preparation method comprises the steps of quantitative raw material weighing, auxiliary agent grinding, constant-temperature accurate grinding, adding of specific components for accurate grinding again, heat preservation, deodorization and degassing, drop casting forming, cooling, packaging, sealed storage and the like. Compared with the prior art, the prescription food is high in safety, and feeding tests of healthy dogs have no abnormity; clinical cases show that the leucocyte number and the inflammatory factor content of sick dogs can be reduced; the intestinal barrier can be repaired, so that the intestinal mucosa repair is accelerated; intestinal flora can be improved, and the content of short-chain fatty acid in excrement is increased; the nutrition state can be maintained, and the weight loss range of sick dogs is reduced.

A system is disclosed that monitors participants in health-related programs, such as weight loss or exercise programs, and that provides automated, personalized health coaching to the program participants. The system includes breath analysis devices that are used by the program participants to generate ketone measurements, and includes a mobile application that runs on mobile devices of the participants and communicates with corresponding breath analysis devices. The system operates generally by monitoring ketone levels (such as acetone levels) and other attributes of the participants and by making personalized, machine-generated changes or updates to such programs to maintain program effectiveness and engagement. In some embodiments the system uses artificial intelligence to classify and coach the participants.

The invention discloses an application of ganoderma lucidum spore oil in preparation of a medicine or health food for improving sarcopenia. Ganoderma lucidum spore oil can effectively improve weight loss and muscle hypofunction induced by glucocorticoid, and improve the holding power and exercise tolerance level of the body; meanwhile, the skeletal muscle mass and the muscle fiber cross sectional area can be increased, and the skeletal muscle tissue morphological structure is improved; in addition, the ganoderma lucidum spore oil can improve the oxidation resistance of the body and skeletal muscle and reduce the oxidative stress level, so that the skeletal muscle injury related to aging is relieved on the whole. Therefore, the ganoderma lucidum spore oil has a definite application value in the aspect of improving the skeletal muscle function.

The invention relates to the field of medicine, and discloses a heterocyclic compound with a GLP-1 receptor agonist effect and application of the heterocyclic compound, the heterocyclic compound is a compound with a structure shown in a formula (I), or an isomer, an isotope labeled compound, a prodrug, or pharmaceutically acceptable salt, ester, hydrate or solvate of the compound. The obvious treatment effect is realized in the aspect of reducing blood sugar or reducing weight.

A weight loss supplement composition is disclosed. The composition comprises a first pre-defined amount of dairy product such that the dairy product is a heavy and lactose-free whipping cream; an effective amount of sugar-free flavoring extract; and a second pre-defined amount of isolate whey protein; wherein the first pre-defined amount of the dairy product, the effective amount of the sugar-free flavoring extract, the second pre-defined amount of the isolate whey protein are mixed to a desired consistency for preparing a weight loss supplement.

This invention belongs to the field of post-harvest quality testing technology for agricultural products, specifically relating to a method for predicting the degree of chilling injury in bitter gourd. The method uses *Bitter Gourd 'Du Ruan'* as the research object, employing segmented pre-cooling treatment to measure indicators such as chilling injury index, respiration rate, weight loss rate, firmness, chlorophyll content, malondialdehyde content, and antioxidant enzyme activity during storage. This determines suitable pre-cooling conditions, explores the impact of different pre-cooling settings on its physiological quality and chilling injury development during storage, and constructs a bitter gourd chilling injury prediction model based on key indicators. The method for predicting the degree of chilling injury in bitter gourd provided by this invention offers a theoretical basis and technical support for optimizing post-harvest cold chain processes for bitter gourd, mitigating low-temperature damage, and extending shelf life.

The invention discloses a Brawertia wevidii for treating irritable bowel syndrome and application thereof, and belongs to the technical field of microorganisms. According to the present invention, the bacterial strain is Blauraceae wettingii (Blauraceae wettingii) MW-022, and the preservation number of the bacterial strain is GDMCC No: 66940; experiments prove that the strain has the effect of improving the symptoms of the irritable bowel syndrome, the weight loss of a mouse with the irritable bowel syndrome is delayed, the visceral sensitivity is remarkably reduced, the time for first-time defecation is delayed, low-grade inflammation is inhibited, oxidative stress is relieved, and meanwhile affective disorder of the mouse is relieved; the irritable bowel syndrome can be effectively treated by independently using the traditional Chinese medicine composition.

1. The name of the design product: fat-losing machine (S05). 2. The use of the design product: for weight loss exercise. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best shows the design points: perspective view.

The invention discloses application of hairyvein agrimony in preparation of a weight-reducing medicine. The weight-losing medicine is a hairyvein agrimony decoction, extract or monomer agrimonin, the effective components in the medicine are agrimonin and derivatives thereof, and STAT3 activity and SOCS3 expression can be inhibited, so that the STAT3-SOCS3 activity is kept in a proper range, and the weight-losing effect is achieved. It is found through experiments that the agrimonin can target SET protein, relieve inhibition of SET on PP2A and promote dephosphorylation of PP2A-mediated STAT3, NF-kB and other signals, so that the activity of the STAT3, the NF-kB and the other signals is inhibited, SOCS3 expression is reduced, and the purpose of weight reduction is achieved. The weight-reducing medicine comprises a hairyvein agrimony decoction, a hairyvein agrimony extract and agrimonin, and human body experiments prove that the hairyvein agrimony decoction and the hairyvein agrimony extract have a remarkable weight-reducing effect.

The present application relates to a kind of compositions containing potato extract and with extended satiety and its preparation method and application, and the composition includes the following weight parts of raw materials: plant extract 30-40 parts, protein component 10-20 parts, dietary fiber component 30-40 parts and auxiliary materials 5-10 parts;Wherein, the plant extract includes potato extract, white kidney bean extract, tea flower extract and lotus leaf extract, the protein component is at least one in pea protein, soybean protein and oat protein, the dietary fiber component is the combination of inulin, resistant dextrin, psyllium husk powder, apple fiber powder and citrus fiber powder.The composition of the present application has significant advantages in controlling body weight and managing satiety, and realizes the weight loss effect of "reducing heat absorption, extending satiety and promoting metabolism" in multiple dimensions, forms sustainable metabolic health support long-term value, and can be used for preparing weight loss body shaping functional food.

The application discloses a kind of slimming traditional Chinese medicine composition and preparation method thereof, it is related to slimming traditional Chinese medicine technical field.Slimming traditional Chinese medicine composition includes the following weight parts of Chinese medicinal materials: 30-45 parts of raw astragalus, 10-15 parts of prepared atractylodes rhizome, 15-23 parts of cassia bark, 20-30 parts of dried tangerine or orange peel, 30-45 parts of lotus leaf, 20-30 parts of raw hawthorn, 15-23 parts of kelp, 10-15 parts of turmeric, 10-15 parts of fried Semen Raphani, 10-15 parts of raw safflower stigma.The preparation method includes the following steps: the weight parts of the above-mentioned Chinese medicinal materials are extracted by water decocting.The traditional Chinese medicine composition of the application has the effects of benefiting qi and invigorating the spleen, resolving phlegm and eliminating dampness, and is also compatible with drugs for warming kidney and assisting yang, eliminating phlegm and resolving mass, and has the combined effects of treating both symptoms and root causes, tonifying deficiency and eliminating excess, which can increase energy consumption of the body, reduce fat generation and storage to achieve the effect of weight loss.The traditional Chinese medicine composition of the application is mainly composed of food-medicines, and can be taken for a long time.

The invention relates to an application of an anti-inflammatory drug in resisting CRS caused by CART treatment. Specifically, in CART treatment, various side effects, such as weight loss, fever and other CRS-related symptoms, of CART, TCRT, antibodies and other immunotherapy can be effectively reduced by using anti-inflammatory drugs.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The present application provides a kind of traditional Chinese medicine composition for weight loss, hypolipidemic and its preparation method and use.The traditional Chinese medicine composition is made of the following raw materials by weight parts: Bai Zhi 10-20 parts, Dang Shen 10-20 parts, Tu Fu Ling 15-25 parts, Dan Shen 15-25 parts, Rou Fu Zhi Shu 5-15 parts, Rou Fu Yi Ren 15-25 parts, Chen Pi 10-20 parts, Fa Ban Xia 10-20 parts, Shan Zha 5-15 parts, Huang Lian Pian 15-25 parts, Chao Jue Ming Zi 15-25 parts, Rou Fu Cang Zhu 5-15 parts, Gan Jiang 5-15 parts, Xiao Tong Cao 2-8 parts.The traditional Chinese medicine composition of the present application is based on the theory of TCM syndrome differentiation, and is reasonable in prescription compatibility, with significant effects of weight loss and lipid-lowering.

The present application provides a kind of metabolism steady state regulation type full nutrition weight loss meal replacement powder, by 82~90 weight parts of endocrine regulation component, 4~8 weight parts of metabolic activation component, 3~5 weight parts of nutrient component and 2~6 weight parts of flavor component, also provides the preparation method of metabolism steady state regulation type full nutrition weight loss meal replacement powder.The present application will realize synchronous intervention to three major core problems of energy metabolism, endocrine coordination, tissue function, reconstructs the metabolic homeostasis of organism, realizes the effective management of body weight.

In one example, a method includes receiving an indication of a body characteristic of a user collected by a sensor and an identifier of an actual choice by the user; deriving a level of health of the user from at least the body characteristic; correlating the identifier to an amount of a nutrient of a food item, or an amount of energy used by a physical activity; deriving an actual reward for actual choice, wherein the actual reward comprises an amount of money, credit or redeemable tokens; implementing the actual reward by providing the user or taking from the user the amount of money, credit or redeemable tokens; and transmitting to a portable device of the user, an indication of the actual reward to enable its presentation to the user.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

The present application belongs to the technical field of yogurt preparation. More specifically, it relates to a kind of broadleaf hand dietary fiber yogurt and its preparation method and application. The present application introduces broadleaf hand dietary fiber into yogurt matrix before fermentation, and successfully prepares broadleaf hand dietary fiber yogurt with significant lipid-lowering function by optimizing co-fermentation process parameters. The present application innovatively introduces broadleaf hand dietary fiber into the yogurt co-fermentation system, and simultaneously realizes texture improvement, flavor optimization and weight loss and lipid-lowering function enhancement under the premise of zero addition of exogenous stabilizer and flavor modifier, significantly improving the overall quality of the product. The present application expands the high-value utilization path of broadleaf hand resources in the field of functional foods, develops natural functional dairy products with weight loss and lipid-lowering effect, meets the current market demand of consumers for healthy, natural and functional foods, and has good application prospect and application value.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards5 to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

1. Name of the product in this design: Fat Burning Machine. 2. Purpose of this design: This design is for weight loss and fitness. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Other situations requiring explanation: The enlarged view of part A of this design is a detailed view of the product.

The present application relates to the technical field of fermented milk, and particularly relates to a normal-temperature zero-sucrose yoghurt and a preparation method thereof.The preparation method of the normal-temperature zero-sucrose yoghurt provided by the present application comprises the following steps: preparing raw cow milk, and adding stabilizers, sweeteners, inulin or xylo-oligosaccharides, whey proteins and honeysuckle extract liquid, and then performing fermentation by using streptococcus thermophilus, lactobacillus bulgaricus and probiotics as fermentation strains.The normal-temperature yoghurt provided by the present application can ensure product flavor and shelf life stability and achieve the effect of weight loss through the synergistic effect of various raw materials.It is verified through animal experiments that the normal-temperature zero-sucrose yoghurt prepared by the present application has the effects of regulating rat weight, body fat rate and weight-related genes during the shelf life.

The application discloses an adjustable balloon system and an adjusting method, which comprise a balloon, a connecting catheter and a filling catheter; the adjustable balloon system further comprises a sealing cover and a facilitator; two ends of the connecting catheter are respectively provided with a connecting end head and a pre-bent end head, one end of the connecting catheter close to the pre-bent end head is connected with the balloon, the pre-bent end head is located in the inner cavity of the balloon, and a self-closing sealing plug is sleeved on one end of the pre-bent end head; the filling catheter and the sealing cover can be movably disassembled with the connecting end head of the connecting catheter; two ends of the filling catheter are respectively connected with a luer joint and a three-way stop valve, and the facilitator is sleeved outside the balloon and the connecting catheter in the compressed state of the balloon. The application can adjust the stable placement of the balloon system and the volume adjustment after implantation according to the self needs of patients, so as to adjust the weight loss effect, realize the quantitative correction of diet, ensure the accurate control of weight loss, meet the different weight loss needs of different user groups and improve the applicability.

1. Name of the product in this design: Fat Burning Machine. 2. Purpose of this design: This design is for weight loss and fitness. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D rendering 1.

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

The invention discloses application of lactobacillus fermentum E1 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus fermentum E1 disclosed by the invention can remarkably promote fat metabolism in the zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in the hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus fermentum E1.

The invention relates to a preparation method of a low-calorie and low-carbohydrate weight-losing main food, which is characterized in that the low-calorie and low-carbohydrate weight-losing main food with the content of 200-350 kilocalories is produced by utilizing the functional effect that insoluble coarse dietary fibers can be expanded into about 7 times of volume after entering human intestinal tracts and absorbing water; enteral emptying is prolonged, so that hunger sensation can be reduced, and happiness of the human body is increased. Food with low calorie and extremely low carbohydrate content is produced and processed by using a method for removing components except insoluble coarse dietary fibers by using a biological function containing cellulase and a compound enzyme of the cellulase and the like; the invention relates to a preparation method of dietary fiber food such as soybean dreg powder, wheat bran powder and the like, wherein the intake of the soybean dreg powder is reduced by 500-1000 kilocalories per day on the basis of target energy.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.